

### REMARKS

Claims 1-35 are pending and subject to restriction. The following table summarizes various features identified by the examiner as constituting patentably distinct species, and applicant's corresponding election:

The number of antibodies to a B-cell antigen administered.	Two (2) antibodies are administered.
The specificity of the antibody, antibodies, or hybrid antibodies to the B cell antigen, including the epitope(s) if one or more antibody to CD22 is administered.	One antibody is specific for the CD20 antigen, the other antibody is specific for epitope B of the CD22 antigen.
Whether each antibody administered is unconjugated (naked) or conjugated, including the identity of the conjugate is a conjugated antibody is administered.	Each of the anti-CD20 and anti-CD22 antibodies are naked antibodies.
Whether the therapeutic composition also comprises a bispecific fusion protein and the targets of the bispecific fusion protein.	The therapeutic composition does not comprise a bispecific fusion protein.
Whether the therapeutic composition further comprises a secondary therapeutic, and if so, what that secondary therapeutic is.	The therapeutic composition further comprises a cytokine as a secondary therapeutic, in particular IFN- $\beta$ .

In addition, the examiner requires applicant to elect a single autoimmune disorder to be treated with the elected therapeutic composition. Applicants elect multiple sclerosis as the disease to be treated.

Claims 1-16, 18, 19, 37 and 38 are readable on the elected species.

Applicants now await the initial Action on the merits. Should there be any other matter requiring applicants' attention, the examiner is invited to contact the undersigned attorney at the local exchange listed below.

Respectfully submitted,

Date June 14, 2002

FOLEY & LARDNER  
Customer Number: 22428





22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5427

Facsimile: (202) 672-5399

By 

 Barbara McDowell *Reg No 35264*  
Attorney for Applicants  
Registration No. 31,640